Straits Times Index
3,280.91 -12.22 (-0.37%) Nikkei
37,628.48 -831.60 (-2.16%) Hang Seng
17,266.79 +65.52 (+0.38%) FTSE 100
8,040.38 0.00 (0.00%) Bitcoin USD
64,306.30 -2,479.66 (-3.71%) CMC Crypto 200
1,389.82 +7.25 (+0.52%)
AZN Jan 2025 105.000 put
| Previous close | 35.40 |
| Open | 35.40 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 105.00 |
| Expiry date | 2025-01-17 |
| Day's range | 35.40 - 35.40 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Alphabet, Microsoft, Southwest earnings: What to watch
Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, underpinning strong demand for its blockbuster drugs and steady sales from partnered medicines. Oncology, the Anglo-Swedish drugmaker's top business, clocked a 26% jump in first-quarter sales to $5.12 billion. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.
ReutersAstraZeneca trounces first-quarter estimates as resilient demand fuels growth
CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes. Combined revenue from partnered medicines, such as breast cancer therapy Enhertu with Daiichi Sankyo and asthma medicine Tezspire with Amgen, jumped by more than 60% in the three-month period, fuelling overall growth. The number two London-listed company by market value reported core earnings per share of $2.06 on a 19% year-on-year rise in total revenue to $12.68 billion.
